Supplementary Table 1. Comparison of baseline characteristics of the retrospective and prospective cohort

Characteristic	Retrospective (n = 98)	Prospective (n = 10)	P-value
Age at US (year)	13.6 (7.7–17.8)	9.4 (3.4–12.3)	0.011
Age at LT (year)	1.1 (0.7–2.8)	1.5 (0.8–2.0)	0.865
Interval from LT to US (year)	11.7 (4.3–15.6)	5.6 (2.1–10.1)	0.037
Sex			0.744
Boys	42 (42.9)	5 (50.0)	
Girls	56 (57.1)	5 (50.0)	
Indication for LT			0.633
Biliary atresia	62 (63.3)	7 (70.0)	
Acute liver failure	13 (13.3)	0	
Malignancy	7 (7.1)	1 (10.0)	
Metabolic disease	6 (6.1)	1 (10.0)	
PFIC	4 (6.1)	1 (10.0)	
Portal vein anomaly	2 (2.0)	0	
Others	4 (4.1)	0	
Laboratory findings at US			
Platelet count ($\times 10^3$/μL)	206.2 ± 69.3	216.3 ± 94.3	0.836
INR	1.0 ± 0.1	1.1 ± 0.1	0.615
Total bilirubin (mg/dL)	0.6 ± 0.8	0.3 ± 0.2	0.02
γ-GT (IU/L)	48.3 ± 209.0	38.0 ± 103.5	0.754
AST (IU/L)	47.2 ± 163.5	49.4 ± 33.8	0.343
ALT (IU/L)	47.9 ± 216.1	52.5 ± 84.9	0.567
ALP (IU/L)	187.1 ± 186.0	322.1 ± 490.0	0.039
Albumin (g/dL)	3.6 ± 0.5	3.5 ± 0.9	0.23
Pathologic parameters			
METAVIR fibrosis grade			0.635
F0	28 (28.6)	4 (40.0)	
F1	43 (43.9)	2 (20.0)	
F2	25 (25.5)	4 (40.0)	
F3	1 (1.0)	0	
F4	1 (1.0)	0	
Necroinflammatory activity grade			0.164
A0	53 (54.1)	5 (50.0)	
A1	32 (32.7)	3 (30.0)	
A2	9 (9.2)	0	
A3	4 (4.1)	2 (20.0)	
LAF score	2.9 ± 1.9	2.6 ± 2.1	0.617
Allograft damage			0.794
No	63 (64.3)	6 (60.0)	
Yes	35 (35.7)	4 (40.0)	

Values are presented as median (IQR), number (%), or mean±SD.
US, ultrasonography; LT, liver transplantation; PFIC, progressive familial intrahepatic cholestasis; INR, international normalised ratio; γ-GT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; METAVIR, Meta-analysis of Histological Data in Viral Hepatitis; LAF, liver allograft fibrosis; IQR, interquartile range; SD, standard deviation.